Modular T-Cell Manufacturing for Scalable Adoptive Cell Therapies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing T cell manufacturing processes for adoptive immunotherapy are not scalable, repeatable, reliable, or efficient, often producing inferior T cell products prone to exhaustion and loss of effector immune cell function, limiting the widespread clinical use of engineered T cell therapies.
Innovation Solution
A method involving obtaining a population of cells, activating and stimulating them with cytokines and antibodies, transducing with a viral vector, and expanding the T cells in a controlled environment using bioreactors, to produce a reproducible and reliable T cell therapeutic.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional T cell manufacturing processes are used, then T cell therapy can be produced, but the process is not scalable, repeatable, or reliable and produces inferior T cell products
Solution Approach 1:
The manufacturing process is divided into distinct modular stages: T cell isolation from patient blood, in vitro activation and expansion using defined cytokine combinations (IL-2, IL-7, IL-15), genetic transduction with viral vectors, and final product formulation. Each module can be independently optimized and validated, improving both reliability and scalability.
Solution Approach 2:
The patent employs controlled variation of culture parameters including cytokine concentrations, cell density, incubation time, and temperature to optimize T cell expansion and activation. Defined media compositions with specific growth factors are used to standardize the manufacturing process across different production batches.
2Quantity of substance
If T cell activation and expansion steps are performed to generate therapeutic doses, then clinically effective T cell numbers are achieved, but the process becomes complex and T cells become exhausted
Solution Approach 1:
T cells are activated and expanded in vitro before genetic transduction and final therapy administration. This preliminary expansion ensures sufficient cell numbers are available for dosing while maintaining cell functionality through controlled culture conditions that prevent exhaustion.
Solution Approach 2:
The manufacturing process maintains continuous T cell culture with sustained cytokine support to promote ongoing proliferation and activation without allowing cells to enter exhaustion states. Fresh media and cytokines are added at optimized intervals to maintain productive expansion.
3Manufacturing precision
If viral transduction is performed to engineer T cells, then antigen-specificity is improved, but the manufacturing process becomes more complex
Solution Approach 1:
Viral vectors serve as intermediaries to deliver genetic material encoding antigen-specific receptors into T cells. The viral transduction system acts as a mediator that enables precise genetic modification while the surrounding culture conditions and purification steps manage the complexity of the overall process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves reproducible, reliable, and scalable production of T cell therapeutics with enhanced expansion and antigen-specific tumor clearance, reducing patient-to-patient variability and enabling cGMP manufacturing processes.
Implementation Method 1
culturing the population of cells in a cell culture medium comprising i) one or more cytokines, ii) an anti-CD3 antibody or CD3-binding fragment thereof, and iii) an anti-CD28 antibody or a CD28-binding fragment thereof
Implementation Method 2
an anti-CD3 antibody or CD3-binding fragment thereof, and an anti-CD28 antibody or a CD28-binding fragment thereof, wherein the culture activates and stimulates the T cells
Implementation Method 3
transducing the population of activated cells with a viral vector
Implementation Method 4
culturing the population of cells in a cell growth medium to expand the transduced T cells
Data Source
AI summary
The invention provides compositions and methods for manufacturing adoptive cell therapies. In particular embodiments, the invention provides methods of harvesting populations of cells, isolating and activating PBMCs, expanding T cells, and administering the T cell therapeutic to a subject in need thereof.